Erdosteine

Erdosteine


visit www.erdosteine.net

Erdosteine is a New Chemical Entity (NCE) entirely developed by Edmond Pharma, starting from the initial synthesis to  patent coverage and international registration.

In the development phase a several molecules potentially effective in the  respiratory area were synthetized by Edmond Pharma. After a deep analysis Erdosteine has been selected as the final candidate for further development.  It has undergone  a complete programme of clinical and pharmacological studies with demonstration of unique characteristics, like:

  • Muco-modulatory activity
  • Anti-bacterial
  • Anti-inflammatory
  • Anti-oxidant

His highly diversified pharmacological profile makes Erdosteine an ideal  molecule for  the treatment of Chronic Bronchitis (CB) and Chronic Obstructive Pulmonary Disease (COPD), both in its stable form and during acute exacerbations.

Erdosteine has proved its efficacy and safety, both in adults and in children, in more than 60 clinical trials  with over 3,000 treated subjects and during more than 10 years’ experience in clinical practice worldwide.
Its clinical efficacy, combined with an excellent safety profile allows Erdosteine to be used in combination with the major  treatments available today for treating  CB and COPD.

Erdosteine is now available in 4 different formulations:

  • 150 mg / 300 mg capsules
  • 225 mg / 300 mg sachets
  • 175 mg dry syrup
  • 300 mg dispersible  tablets

Erdosteine is the only mucolytic currently  recommended in the guidelines of the American College of Chest Physicians for improving expectoration in chronic bronchitis.

In the United States, Erdosteine is currently in clinical Phase II development, with an active IND (Investigational New Drug) at the FDA.

Erdosteine holds several international patents on use and processing.
 
Erdosteine is approved and marketed as an under prescription drug in more than forty countries around the world.

Contact
Pierfrancesco Manzo
pierfrancesco.manzo@recipharm.com 



Country Marketed by

Algeria
Argentina
Armenia
Austria
Azerbaijan 
Bahrain
Belarus
Belgium
Bulgaria
Cambodia
China
Colombia
Czech Republic
Ecuador
Egypt
Finland
France
Georgia
Greece

Greece
Hungary
Indonesia

Indonesia
Israel
Jordan
Kazakhstan
Korea
Luxembourg
Mexico

Mexico
Moldova
Oman
Pakistan
Philippines

Philippines
Poland
Portugal
Qatar
Romania
Russia
Slovakia
South Korea
Switzerland
Turkey

Turkey
Venezuela
Vietnam
Hikma Pharmaceuticals
Quimica Montpellier

CSC - Angelini Group
CSC - Angelini Group 
CSC - Angelini Group
Hikma Pharmaceuticals
CSC - Angelini Group
Rottapharm - Madaus
CSC - Angelini Group
Dexa Medica
Eddingpharm

Aplicaciones Farmaceuticas
CSC - Angelini Group
Grunenthal Ecuatoriana
Global Napi
Orion Pharma
Lab. Pharma 2000

CSC - Angelini Group
Faran
Bros

CSC - Angelini Group
Dexa Medica
Ferron
Megapharm
Hikma Pharmaceuticals

CSC - Angelini Group
Daewoong
Rottapharm Madaus
Aplicationes Farmaceuticas

Productos Cientificos
CSC - Angelini Group
Hikma Pharmaceuticals
Brookes Pharmaceuticals
GSK Philippines

OEP Philippines
CSC - Angelini Group
Rottapharm Madaus
Hikma Pharmaceuticals
CSC - Angelini Group
CSC - Angelini Group
CSC - Angelini Group
Daewoong
Vifor

Eczacibasi Pharmaceuticals Co
Sandoz
Grunenthal Venezolana
Dexa Medica

Erdosteine is a NCE entirely developed by Edmond Pharma,from initial laboratory synthesis to international patenting and registration